Pharma Marketing Network

Pharma will be faced with numerous challenges in 2006 according to experts who have responded to the 2006 Pharma Trend Survey hosted by Pharma...

From time to time, Pharma Marketing News hosts surveys of subscribers and visitors to the website. These surveys give you an opportunity to offer...

Tom McKillop, former CEO of AstraZeneca, seems a bit schizophrenic when it comes to describing his image of the pharma industry vs. the reality...

This is a good time of the year to communicate a mission statement of sorts. Personal Point of View Blogs, of course, are highly...

See Corrections and Amplification below."We get no respect," said a Pfizer representative, "no respect at all I tell you! Last week we ran an...

Merck's new "Patients Come First" TV ad starts off with this question: "If you ran a pharmaceutical company, what would you change?" I thought...

Pharma Marketing Network offers a free monthly e-newsletter, networking, resources, conference calendar, and a directory of pharmaceutical marketing vendors.

Biotechnology companies with a product commercialization strategy are deploying field-based medical science liaisons (MSLs) to increase awareness of a therapeutic market, support clinical trials, and educate the healthcare community on appropriate product utilization. Attracting experienced MSLs to smaller or younger companies remains a significant challenge for MSL directors. This article provides helpful suggestions that biotech and other science-based companies can use to build their MSL force.

This article discusses the often misinterpreted safe harbor and whether MSLs enjoy such protection when disseminating off-label information.

If we define Medical Science Liaison (MSL) training as enabling an MSL to adopt a desired behavior or fulfill a desired performance expectation, we can readily see how most of what we call training is not really training at all